Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Inaxaplin in Hepatic Impairment
NCT06529796Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of inaxaplin in focal segmental glomerulosclerosis (FSGS) (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Concentration Versus Time Curve From Time of Dosing Extrapolated to Infinity. Started Aug 2024; status: completed.
02
Drugs
inaxaplin
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT06529796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06529796.